| Document and Entity Information | Nov. 01, 2022 |
| Document And Entity Information [Line Items] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001834645 |
| Document Type | 8-K/A |
| Document Period End Date | Nov. 01, 2022 |
| Entity Registrant Name | Peak Bio, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-39951 |
| Entity Tax Identification Number | 85-2448157 |
| Entity Address, Address Line One | 3350 W. Bayshore Rd. |
| Entity Address, Address Line Two | Suite 100 |
| Entity Address, City or Town | Palo Alto |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94303 |
| City Area Code | (650) |
| Local Phone Number | 549-9103 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | This Amendment No. 1 on Form 8-K/A (“Form 8-K/A”) amends the Current Report on Form 8-K of Peak Bio, Inc., a Delaware corporation (the “Company”), filed on November 7, 2022 (the “Original Report”), in which the Company reported, among other events, the completion of the Business Combination (as defined in the Original Report). This Form 8-K/A is being filed in order to include the (i) unaudited carve-out condensed consolidated financial statements of Peak Bio Co., Ltd. (“Peak Bio”) as of September 30, 2022 and for the nine months ended September 30, 2022 and 2021, (ii) unaudited pro forma condensed combined financial information of the Company and the related notes thereto as of and for the nine months ended September 30, 2022 and for the year ended December 31, 2021 and (iii) management’s discussion and analysis of financial condition and results of operations of Peak Bio for the nine months ended September 30, 2022 and 2021. This Form 8-K/A does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company or its subsidiaries, including Peak Bio, subsequent to the filing date of the Original Report. The information previously reported in or filed with the Original Report is hereby incorporated by reference to this Form 8-K/A. |
| Common Stock [Member] | |
| Document And Entity Information [Line Items] | |
| Security 12b Title | Common stock, par value $0.0001 per share |
| Trading Symbol | PKBO |
| Security Exchange Name | NASDAQ |
| Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At An Exercise Price Of 11.50 Per Share [Member] | |
| Document And Entity Information [Line Items] | |
| Security 12b Title | Warrants, each whole warrant exercisable for one share of common stock for $11.50 per share |
| Trading Symbol | PKBOW |
| Security Exchange Name | NASDAQ |
